Mode
Text Size
Log in / Sign up

Non-intubated VATS shows lower hazard for OS and DFS/RFS compared with intubated VATSSurgery without a breathing tube shows promise for lung cancer

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that NIVATS shows lower hazard for OS and DFS/RFS but results are limited by potential selection bias.

This meta-analysis evaluates the oncologic outcomes of non-intubated video-assisted thoracoscopic surgery (NIVATS) compared with intubated VATS in patients with non-small cell lung cancer (NSCLC). The study focuses on primary outcomes including overall survival (OS) and disease-free survival or recurrence-free survival (DFS/RFS), alongside secondary metrics such as R0 resection rates and lymph node harvest counts.

The meta-analysis reported a lower pooled hazard for OS in the NIVATS group (HR 0.66; 95% CI 0.48-0.91) and a lower pooled hazard for DFS/RFS (HR 0.66; 95% CI 0.50-0.87). No significant differences were observed in R0 resection rates or the total number of lymph nodes harvested. A borderline lower risk of recurrence was noted following NIVATS.

The authors highlight several limitations, including selection bias and residual confounding regarding survival advantages, as NIVATS is often reserved for patients with favorable tumor features or better cardiopulmonary reserve. The GRADE certainty for OS and DFS/RFS is low. Clinical application suggests that while NIVATS does not appear to compromise long-term outcomes compared to intubated VATS, its use should be restricted to experienced teams in appropriate clinical scenarios.

How this fits prior evidence

This meta-analysis addresses a gap regarding the oncologic safety of non-intubated surgical techniques in NSCLC. While prior coverage has established various systemic and targeted therapies for advanced NSCLC, such as ivonescimab plus chemotherapy or sacituzumab tirumotecan combinations, this study specifically evaluates the impact of surgical approach (NIVATS vs. intubated VATS) on survival outcomes.

When patients face lung cancer, the way they are managed during surgery is critical. Some patients undergo surgery while being intubated, which means a tube is placed in their airway to help them breathe. Other patients undergo a method called NIVATS, where they are not intubated and instead use spontaneous ventilation. This study looked at how these two methods compare for people with non-small cell lung cancer.

The data shows that patients who underwent the surgery without a breathing tube (NIVATS) had lower risks of death and lower risks of their cancer returning compared to those who were intubated. However, researchers noted that this benefit might be partly due to selection bias. This means doctors often choose the non-intubated method for patients who are already in better physical shape or have less severe tumors.

While the results suggest NIVATS is a safe and feasible option, the evidence is currently considered low certainty. Because many of the studies were not randomized, we cannot be certain if the surgery itself caused the better outcomes or if it was just the types of patients chosen for that specific method. More large-scale trials are needed to confirm these findings.

What this means for you:
Surgery without a breathing tube shows potential survival benefits for lung cancer patients, but more research is needed.

Common questions

What is the difference between NIVATS and traditional surgery?

NIVATS is a type of surgery where the patient does not have a breathing tube inserted. Instead, they use spontaneous ventilation. The other method involves intubated surgery, where a tube is used to manage the airway during the procedure.

Does the non-intubated method improve survival for lung cancer patients?

The study found lower risks of death and lower risks of cancer returning for those who had surgery without a breathing tube. However, these results are currently considered to have low certainty because of potential selection bias.

Is the non-intubated method safe for lung cancer patients?

The findings suggest that the non-intubated method is a feasible option and does not seem to compromise long-term outcomes. However, it should be performed by experienced teams who can carefully select the right patients.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedAug 2026
View Original Abstract ↓
Non-intubated video-assisted thoracoscopic surgery (NIVATS) is increasingly used for selected non-small cell lung cancer (NSCLC) patients, but its long-term oncologic outcomes versus conventional VATS remain unclear. We therefore conducted this systematic review and meta-analysis to compare long-term oncologic outcomes between NIVATS and conventional intubated video-assisted thoracoscopic surgery (VATS). We searched major databases and trial registries through June 30, 2026 for comparative studies evaluating NIVATS or spontaneous ventilation VATS versus intubated or mechanical ventilation VATS in NSCLC. The primary outcomes were overall survival (OS) and disease-free survival or recurrence-free survival (DFS/RFS). Secondary oncologic outcomes included recurrence, R0 resection, total lymph node assessment, N1 and N2 lymph node assessment, and lymph node station or group assessment. Hazard ratios (HRs), risk ratios (RRs), and mean differences (MDs) with their 95% confidence intervals (CIs) were pooled using random-effects models. Risk of bias was assessed using the Risk of Bias 2 (RoB 2) tool and the Newcastle-Ottawa Scale (NOS), and the certainty of evidence was evaluated using the GRADE framework. Seventeen comparative studies were included in the qualitative synthesis. NIVATS was associated with lower pooled hazards for OS compared with intubated VATS (HR 0.66, 95% CI 0.48-0.91; I2 = 0.0%; GRADE certainty: low) and lower pooled hazards for DFS/RFS (HR 0.66, 95% CI 0.50-0.87; I2 = 0.0%; GRADE certainty: low). These findings remained stable in sensitivity analyses. No significant difference was observed in total lymph nodes harvested or R0 resection rate. Recurrence showed a borderline lower risk after NIVATS, although follow-up definitions varied across studies. The randomized study was judged as having some concerns, and observational studies were generally moderate to high quality. In selected NSCLC patients, NIVATS does not appear to compromise long-term oncologic outcomes versus conventional intubated VATS. The observed survival advantage likely reflects selection bias and residual confounding, as NIVATS is often used in patients with favorable tumor features, operative suitability, or cardiopulmonary reserve. These findings support NIVATS as feasible under strict selection by experienced teams. Prospective multicenter studies with standardized protocols and long-term follow-up are needed to confirm its oncologic safety. crd.york.ac.uk/prospero/display_record.php?ID=CRD420261437783, identifier CRD420261437783.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.